
Cancel anytime
- Chart
- Upturn Summary
- Highlights
- Revenue
- Valuation
Upturn AI SWOT
- About


Xenon Pharmaceuticals Inc (XENE)



- BUY Advisory
- SELL Advisory (Profit)
- SELL Advisory (Loss)
- Profit
- Loss
- Pass (Skip investing)


(see disclosures)
- ALL
- YEAR
- MONTH
- WEEK
Upturn Advisory Summary
08/14/2025: XENE (1-star) has a low Upturn Star Rating. Not recommended to BUY.
1 Year Target Price $55.06
1 Year Target Price $55.06
14 | Strong Buy |
5 | Buy |
0 | Hold |
0 | Sell |
0 | Strong Sell |
Analysis of Past Performance
Type Stock | Historic Profit -27.03% | Avg. Invested days 23 | Today’s Advisory Consider higher Upturn Star rating |
Upturn Star Rating ![]() ![]() | Upturn Advisory Performance ![]() | Stock Returns Performance ![]() |
![]() ![]() | ![]() ![]() |
Key Highlights
Company Size Mid-Cap Stock | Market Capitalization 2.93B USD | Price to earnings Ratio - | 1Y Target Price 55.06 |
Price to earnings Ratio - | 1Y Target Price 55.06 | ||
Volume (30-day avg) 19 | Beta 1.17 | 52 Weeks Range 26.74 - 46.00 | Updated Date 08/15/2025 |
52 Weeks Range 26.74 - 46.00 | Updated Date 08/15/2025 | ||
Dividends yield (FY) - | Basic EPS (TTM) -3.55 |
Analyzing Revenue: Products, Geography and Growth
Revenue by Products
Product revenue - Year on Year
Earnings Date
Report Date 2025-08-11 | When - | Estimate -0.99 | Actual 1.07 |
Profitability
Profit Margin - | Operating Margin (TTM) -969.84% |
Management Effectiveness
Return on Assets (TTM) -22.03% | Return on Equity (TTM) -31.6% |
Valuation
Trailing PE - | Forward PE - | Enterprise Value 2448106130 | Price to Sales(TTM) 390.26 |
Enterprise Value 2448106130 | Price to Sales(TTM) 390.26 | ||
Enterprise Value to Revenue 326.41 | Enterprise Value to EBITDA -11.81 | Shares Outstanding 77105800 | Shares Floating 70881895 |
Shares Outstanding 77105800 | Shares Floating 70881895 | ||
Percent Insiders 0.14 | Percent Institutions 105.56 |
Upturn AI SWOT
Xenon Pharmaceuticals Inc

Company Overview
History and Background
Xenon Pharmaceuticals Inc. is a biopharmaceutical company founded in 1996. It focuses on developing novel therapeutics for neurological disorders. The company has evolved from a genomics-based research firm to a clinical-stage biopharmaceutical developer.
Core Business Areas
- Neurology: Focuses on developing therapies for epilepsy and other neurological disorders.
- Rare Diseases: Development of therapies for rare neurological disorders.
- Preclinical Programs: Discovery and development of novel therapeutic candidates in various areas.
Leadership and Structure
The leadership team includes Ian Mortimer (President and CEO). The company is structured around research, clinical development, and commercialization functions.
Top Products and Market Share
Key Offerings
- XEN1101 (active epilepsy): A Kv7 potassium channel modulator being developed for the treatment of focal epilepsy. Phase 3 clinical trials are underway. Competitors include generic anti-epileptic drugs (AEDs) and newer branded AEDs from companies like UCB, Eisai, and SK Biopharmaceuticals. Estimated revenue not publicly discolsed. Market share is still emerging.
Market Dynamics
Industry Overview
The biopharmaceutical industry is characterized by high R&D costs, regulatory hurdles, and intense competition. There is a significant unmet need for novel therapies in neurological disorders.
Positioning
Xenon is positioned as a specialty biopharmaceutical company focused on novel mechanisms of action in specific neurological indications. Their competitive advantage lies in their expertise in Kv7 potassium channel modulation.
Total Addressable Market (TAM)
The TAM for epilepsy treatments is estimated to be billions of dollars annually. Xenon is positioned to capture a portion of this market with XEN1101 if approved.
Upturn SWOT Analysis
Strengths
- Strong expertise in Kv7 potassium channel modulation
- Promising clinical pipeline
- Experienced management team
- Strong intellectual property position
Weaknesses
- Reliance on a limited number of clinical programs
- High R&D expenses
- Dependence on regulatory approvals
- Limited commercial infrastructure
Opportunities
- Successful clinical trials for XEN1101
- Expansion into new neurological indications
- Partnerships with larger pharmaceutical companies
- Advancements in precision medicine
Threats
- Clinical trial failures
- Regulatory setbacks
- Competition from established pharmaceutical companies
- Generic erosion of existing products
Competitors and Market Share
Key Competitors
- UCB (UCBJF)
- Eisai (ESALY)
- SK Biopharmaceuticals (326030.KS)
Competitive Landscape
Xenon faces competition from established pharmaceutical companies with broader product portfolios and more extensive commercial infrastructure. Xenon's advantage lies in its focus on novel mechanisms of action and specific neurological indications.
Growth Trajectory and Initiatives
Historical Growth: Historical growth has been limited due to the lack of commercial products. The company's growth is primarily reflected in the expansion of its clinical pipeline.
Future Projections: Future growth is highly dependent on the successful development and commercialization of XEN1101 and other pipeline candidates. Analyst estimates vary widely depending on the perceived likelihood of success.
Recent Initiatives: Recent initiatives include the ongoing Phase 3 clinical trials for XEN1101 and the advancement of preclinical programs.
Summary
Xenon Pharmaceuticals is a clinical-stage biopharmaceutical company with a focus on neurological disorders. The success of XEN1101 is critical to the company's future. While Xenon possesses strengths in Kv7 potassium channel modulation and a promising clinical pipeline, it faces risks associated with clinical trials, regulatory approvals, and competition. Future growth is contingent upon successfully navigating these challenges and capitalizing on opportunities in the neurology space.
Peer Comparison
Sources and Disclaimers
Data Sources:
- Xenon Pharmaceuticals Inc. Investor Relations
- Company SEC Filings
- Analyst Reports
- Industry Publications
Disclaimers:
This analysis is for informational purposes only and should not be considered investment advice. Investment decisions should be based on individual research and consultation with a qualified financial advisor. Market share data is estimated and may not be precise.
AI Summarization is directionally correct and might not be accurate.
Summarized information shown could be a few years old and not current.
Fundamental Rating based on AI could be based on old data.
AI-generated summaries may have inaccuracies (hallucinations). Please verify the information before taking action.
About Xenon Pharmaceuticals Inc
Exchange NASDAQ | Headquaters Burnaby, BC, Canada | ||
IPO Launch date 2014-11-05 | CEO - | ||
Sector Healthcare | Industry Biotechnology | Full time employees 316 | Website https://www.xenon-pharma.com |
Full time employees 316 | Website https://www.xenon-pharma.com |
Xenon Pharmaceuticals Inc., a neuroscience-focused biopharmaceutical company, engages in the discovery, development, and delivery of therapeutics to treat patients with neurological and psychiatric disorders in Canada. Its product candidates include Azetukalner, a selective Kv7 potassium channel opener in Phase 3 clinical development for the treatment of epilepsy, including focal onset seizures, and primary generalized tonic-clonic seizures, as well as neuropsychiatric disorders, such as major depressive disorder and bipolar depression. The company has a license and collaboration agreement with the Neurocrine Biosciences, Inc. for the development of NBI-921352, a Nav1.2/1.6 sodium channel inhibitor that is in Phase 1 clinical trials for the treatment of certain types of epilepsy. Xenon Pharmaceuticals Inc. was incorporated in 1996 and is headquartered in Burnaby, Canada.

Note: This website is maintained by Upturn Corporation, which is an investment adviser registered with the U.S. Securities and Exchange Commission. Such registration does not imply a certain level of skill or training. Investing in securities has risks. Past performance is no guarantee of future returns. No assurance is provided as to any particular investment return, and you may lose money using our services. You are strongly advised to consult appropriate counsel before making any investments in companies you learn about through our services. You should obtain appropriate legal, tax, investment, accounting, and other advice that takes into account your investment portfolio and overall financial situation. You are solely responsible for conducting due diligence on a potential investment. We do not affect trades for you. You will select your own broker through which to transact. Investments are not FDIC insured, they are not guaranteed, and they may lose value. Please see the Privacy Policy, Terms of Use, and Disclosure for more information.